|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2007; 50:409-418, doi:10.1016/j.jacc.2007.02.073
(Published online 31 July 2007). © 2007 by the American College of Cardiology Foundation |
Molecular Cardiology Research Institute and Division of Cardiology, Department of Medicine, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts.
Manuscript received February 14, 2007; accepted February 21, 2007.
* Reprint requests and correspondence: Dr. Richard H. Karas, Molecular Cardiology Research Institute, Box #80, Tufts-New England Medical Center, 750 Washington Street, Boston, Massachusetts 02111. (Email: rkaras{at}tufts-nemc.org).
Objectives: We sought to assess the relationship between the magnitude of low-density lipoprotein cholesterol (LDL-C) lowering and rates of elevated liver enzymes, rhabdomyolysis, and cancer.
Background: Although it is often assumed that statin-associated adverse events are proportional to LDL-C reduction, that assumption has not been validated.
Methods: Adverse events reported in large prospective randomized statin trials were evaluated. The relationship between LDL-C reduction and rates of elevated liver enzymes, rhabdomyolysis, and cancer per 100,000 person-years was assessed using weighted univariate regression.
Results: In 23 statin treatment arms with 309,506 person-years of follow-up, there was no significant relationship between percent LDL-C lowering and rates of elevated liver enzymes (R2 <0.001, p = 0.91) or rhabdomyolysis (R2 = 0.05, p = 0.16). Similar results were obtained when absolute LDL-C reduction or achieved LDL-C levels were considered. In contrast, for any 10% LDL-C reduction, rates of elevated liver enzymes increased significantly with higher statin doses. Additional analyses demonstrated a significant inverse association between cancer incidence and achieved LDL-C levels (R2 = 0.43, p = 0.009), whereas no such association was demonstrated with percent LDL-C reduction (R2 = 0.09, p = 0.92) or absolute LDL-C reduction (R2 = 0.05, p = 0.23).
Conclusions: Risk of statin-associated elevated liver enzymes or rhabdomyolysis is not related to the magnitude of LDL-C lowering. However, the risk of cancer is significantly associated with lower achieved LDL-C levels. These findings suggest that drug- and dose-specific effects are more important determinants of liver and muscle toxicity than magnitude of LDL-C lowering. Furthermore, the cardiovascular benefits of low achieved levels of LDL-C may in part be offset by an increased risk of cancer.
| ||||
Related articles in JACC:
This article has been cited by other articles:
|
|
 |
|
  R. S. Elkeles, I. F. Godsland, M. D. Feher, M. B. Rubens, M. Roughton, F. Nugara, S. E. Humphries, W. Richmond, M. D. Flather, and for the PREDICT Study Group Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study Eur. Heart J., June 23, 2008; (2008) ehn279v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Byers Statins, Breast Cancer, and an Invisible Switch? Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1026 - 1027. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ramasubbu, J. Estep, D. L. White, A. Deswal, and D. L. Mann Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 415 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al. Highlights of the year in JACC 2007. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Rembold Age predicts cancer incidence better than statin-induced low-density lipoprotein level. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 90 - 91. [Full Text] [PDF]
|
|
|
|
|
|
J. Kjekshus Risk associated with statin treatment. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 91 - 91. [Full Text] [PDF]
|
|
|
|
|
|
A. A. Alsheikh-Ali and R. H. Karas Reply. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 92 - 92. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Strandberg Low low-density lipoprotein cholesterol and cancer risk. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 91 - 92. [Full Text] [PDF]
|
|
|
|
|
|
E. A. Platz Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2175 - 2180. [Full Text] [PDF]
|
|
|
|
|
|
J. C. LaRosa Means and Ends of Statins and Low-Density Lipoprotein Cholesterol Lowering J. Am. Coll. Cardiol., July 31, 2007; 50(5): 419 - 420. [Full Text] [PDF]
|
|
|
|
|
|
A. N. DeMaria and O. Ben-Yehuda Low-Density Lipoprotein Reduction and Cancer: Not Definitive But Provocative J. Am. Coll. Cardiol., July 31, 2007; 50(5): 421 - 422. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Shor, J. Wainstein, D. Oz, M. Boaz, Z. Matas, A. Fux, and A. Halabe Low Serum LDL Cholesterol Levels and the Risk of Fever, Sepsis, and Malignancy Ann. Clin. Lab. Sci., January 1, 2007; 37(4): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
